Abstract
Colicin production in Escherichia coli (E. coli) strains represents an important trait with regard to microbial survival and competition in the complex intestinal environment. A novel colicin type, colicin Z (26.3 kDa), was described as a product of an original producer, extraintestinal E. coli B1356 strain, isolated from the anorectal abscess of a 17 years-old man. The 4,007 bp plasmid (pColZ) was completely sequenced and colicin Z activity (cza) and colicin Z immunity (czi) genes were identified. The cza and czi genes are transcribed in opposite directions and encode for 237 and 151 amino acid-long proteins, respectively. Colicin Z shows a narrow inhibitory spectrum, being active only against enteroinvasive E. coli (EIEC) and Shigella strains via CjrC receptor recognition and CjrB- and ExbB-, ExbD-mediated colicin translocation. All tested EIEC and Shigella strains isolated between the years 1958–2010 were sensitive to colicin Z. The lethal effect of colicin Z was found to be directed against cell wall peptidoglycan (PG) resulting in PG degradation, as revealed by experiments with Remazol Brilliant Blue-stained purified peptidoglycans and with MALDI-TOF MS analyses of treated PG. Colicin Z represents a new class of colicins that is structurally and functionally distinct from previously studied colicin types.
Similar content being viewed by others
Introduction
Both commensal and pathogenic Escherichia coli strains encode systems for competition among bacterial strains/species allowing survival in the complex intestinal environment. Competition is often driven by the production of bacteriocins, i.e., antibacterial proteins and peptides that selectively kill closely related species1. E. coli strains have been shown to produce two different bacteriocin types including colicins and microcins2,3,4,5. Microcins are low molecular weight oligopeptides (<12 kDa) compared to colicins which are proteins with molecular weight between 10 and 92 kDa. Microcins can be chromosomally or plasmid encoded, whereas all colicin types are plasmid encoded3,4,5,6,7.
From an ecological perspective, bacteriocin production appears to facilitate the invasion of a particular bacterial strain into an established microbial community. It may also mediate defense against invasion of other strains into the occupied niche8,9,10. Moreover, bacteriocinogeny has been shown to be an important feature of probiotic E. coli strains, typically producing, at least, one bacteriocin type11. In addition, an association between the production of several bacteriocin types and the presence of bacterial virulence determinants has been previously described, suggesting that bacteriocins play a role in the colonization capacity of E. coli strains12,13,14,15,16,17.
Colicins are the most extensively studied bacteriocins produced by Gram-negative bacteria and to date, the production of 25 different colicin types have been clearly demonstrated in E. coli strains3,4,7 with the newest type (type R) having been described in 201418. Until now, all well-characterized colicins were plasmid-encoded domain-containing proteins, except for the plasmid-encoded polypeptide colicin JS, where no domains have been identified7. Known colicin types differ in a number of characteristics including mechanism of their release from the producer cell, types of translocation systems used to traverse the cell envelope, mechanism of killing action, receptor specificity, as well as several others3,4.
In this study, a novel colicin, type Z, isolated from the extraintestinal E. coli strain B1356 (pColZ) strain is described in detail, including a characterization of the original producer strain, the complete colicin Z plasmid sequence (pColZ), and identification of the genes responsible for colicin activity (cza) and immunity (czi). Prevalence of the colicin Z activity gene among E. coli strains of different origins and the colicin Z activity spectrum were tested. In addition, the colicin Z receptor, translocation system, and mode of action were determined.
Results
Identification of a colicin Z producer
The original colicin Z producer E. coli B1356 (Table 1) was identified as extraintestinal pathogenic E. coli belonging to phylogenetic group D, which contained 4 out of the 20 tested virulence determinants (fimA, iucC, aer, and pap). In the E. coli B1356 strain, none of the tested bacteriocin determinants were detected. From the set of standard indicator strains, the E. coli B1356 strain inhibited only the growth of S. sonnei 17. Based on these results we suggested that this was a novel colicin type, encoded by E. coli B1356 strain, which we named colicin Z.
Characterization of pColZ and identification of the colicin activity and immunity genes
The colZ plasmid consists of 4,007 base pairs with a GC content of 43.2%. The complete nucleotide sequence of plasmid ColZ was deposited in the GenBank under accession number MK5999282. pColZ has a unique BamHI restriction site, which was used as a reference point in the presentation of the pColZ genetic map (Fig. 1A). pColZ comprises 12 predicted open reading frames (ORFs) encoding polypeptides longer than 50 amino acids (Table 2). The putative origin of plasmid replication was identified between positions 55 bp to 637 bp on pColZ and is similar (35.6%) to the ori site of S. flexneri plasmid pSF301-1 (GenBank acc. no. JF813186). A primosome assembly site for pColZ was identified between positions 82 and 147, and this 66 bp sequence was 98.5% identical to the phiX174 primosome assembly site identified in plasmid pHUSEC. 2011-3 (Gen Bank acc. no. HE610902). A 156 bp-long ORF1 with 56.4% similarity to the plasmid replication gene and also a 153 bp-long ORF5 with low identity 45.7% to the mobB gene were identified on pColZ (Table 2).
Using a BLAST search for amino acid sequence similarities in the UniProt database (Table 2), an ORF6 (714 bp) at plasmid positions 1114–1827 was identified as the putative colicin Z activity gene (cza) based on its low similarity (44.9%) to colicin type 7 (colicin JS) from Yersinia enterocolitica (GenBank acc. no. A0A0T9U2E6) and (39.2%) to colicin A from Serratia fonticola AU-AP2C (GenBank acc. no. U2N7R4). The ORF6 gene was cloned (resulting in pColZ46) (Table 1) and the recombinant strain E. cloni pColZ46 inhibited the growth of the indicator strain S. sonnei 17 indicating the correct identification of cza. A final concentration of 0.02% arabinose was used for induction of E. cloni pColZ46 and for visualization of inhibition zone on indicator strain. Putative promoter regions (−10 and −35), SOS box, and ribosome binding site sequences (S.D.) are indicated in the Fig. 1B. The promoter region upstream of cza gene contains a highly conserved −35 region (TTGACG), and a less-conserved −10 region (TAACAT). Similar promoter regions were described upstream of colicin activity gene on pColE1 and pColJS7,19. While majority (over 75%) of enteric bacteriocin promoters contain two overlapping SOS boxes, the pColZ have a single SOS box similar to promoters of klebicins C and D20. The inductibility of colicin Z synthesis by the SOS response was measured after mitomycin C treatment (0.5 μg ml−1). Highest colicin Z dilution that resulted in a clear zone of growth inhibition and the last dilution that resulted in the turbid zones on the lawn of sensitive indicator strain E. coli O164 was measured. Induction of colicin Z in the culture supernatants led to increase in colicin activity of 1 to 2 orders of magnitude in both, the original producer E. coli B1356 and in the recombinant strain E. coli pColZ46.
The Colicin Z immunity gene (czi, ORF9) was found adjacent to the cza gene and is transcribed in the opposite direction compared to cza. The czi gene showed 34.7% identity to a hypothetical protein from Serratia rubidaea (WP_054306871.1). A recombinant plasmid pColZ99, containing czi, was transformed to E. coli O164 (a strain susceptible to colicin Z) and induction with 0.02% arabinose resulted in resistance to colicin Z. The colicin Z immunity protein was predicted as a cytoplasmic membrane protein with four transmembrane segments, similar to colicin A immunity protein21. No signal peptide sequence was identified in the colicin Z immunity protein.
The average GC content of the cza and czi genes was found to be 39%, while that of remaining plasmid was 45%, suggesting acquisition through horizontal gene transfer.
The deduced amino acid sequence (237 amino acids) of colicin Z (26.3 kDa) was compared with amino acid sequences of 25 previously characterized colicin types. Colicin JS, the smallest known colicin type (10.4 kDa) and first identified in S. sonnei strain7, was found as the most closely related colicin type (Supplementary Fig. S1). The Colicin Z immunity protein contains 151 amino acids with a calculated molecular mass 17.7 kDa, and showed no similarity to previously described colicin immunity proteins. While N-terminal part of colicin Z protein sequence shows similarity to the translocation domains of colicin D and colicin A (Fig. 1C, Supplementary Fig. S2), the central domain between the amino acids 121 and 171 shows homology to a non-lysosomal glucosylceramidase (GenBank acc. no. A0A0A9X393) and a metalloprotease (A0A060LZ15). The C-terminal part of colicin Z protein shows similarity to colicin JS (A0A0T9U2E6).
Colicin Z inhibitory spectrum
E. coli B1356 producing colZ was active against only 6.7% (38 from 563) of the tested bacteria and its inhibitory spectrum comprised EIEC O143 and O164 strains, as well as different Shigella strains (Table 3, Supplementary Table S1).
Prevalence of colicin Z gene among E. coli strains
The cza gene was not detected in any of tested E. coli strains (n = 475) (Table 3, Supplementary Table S2).
Identification of colicin Z receptor and translocation of colicin Z to a susceptible bacterium
Based on the antimicrobial spectrum of colicin Z, which showed similarity to the colicin JS inhibitory spectrum7,22, the cjrABC operon encoding colJS receptor (GenBank acc. no. AF283288.1) was analyzed (Table 4). Recombinant pBAD/HisB plasmids containing combinations of cjr genes were constructed and transformed to E. coli DH10B cells (Table 4). Acquisition of the cjrBC genes resulted in susceptibility to colZ (Table 4). For identification of the colZ translocation system, a set of knockout strains were transformed using a pBAD/HisB vector containing cjrBC genes (Table 1) and tested for susceptibility to colZ. An exbB and exbD mutants were not susceptible to colZ, while tonB mutants and tolA, -B, -Q, were susceptible. ColZ recognizes CjrC receptor and uses CjrB- and ExbB-, ExbD-mediated translocation.
Colicin Z purification and mode of killing action
According to the transcriptional orientation of the colicin Z activity and immunity genes on the ColZ plasmid, the mode of colicin Z action is consistent with either pore-forming or peptidoglycan (PG)-directed activity but not with DNA or RNA nuclease activity3,4. E. coli TOP10F′containing the pColZ46 encoding colicin Z with an N-terminal His tag was constructed and used for colicin Z purification. Following purification, colicin Z (26.3 kDa) activity was 104 arbitrary units per µl (Fig. 2A,B; Supplementary Fig. S3).
Potential pore-forming activity of purified colicin Z protein was tested by conductance measurements on black lipid membranes. Extremely low activity was detected on asolectin membranes and membranes made from E. coli polar extracts. Moderate pore-forming activity was detected on membranes made from synthetic phospholipid DPhPG (1,2-diphytanoyl-sn-glycero-3-phospho-(1′-rac-glycerol)) (pores of conductance about 2.8 pS). Low single-pore conductance together with weak pore-forming activity was considered inconsistent with pore-formation as the principal mode of action of colZ.
Remazol Brilliant Blue (RBB)-stained purified peptidoglycan (see Methods) was used to test the activity of purified colZ on PG. The absorbance of dye released from the samples of RBB-PG incubated with active, purified colicin Z and controls including lysozyme, denatured purified colZ, distilled water, and purified lysate of E. coli TOP10F′ pBAD/HisB (without the cza gene) was measured at 595 nm. An average of three independent measurements (each with two technical replicates) is shown in Fig. 3A. An increasing signal was detected with an increased concentration of active colZ and lysozyme but not with negative controls. Compared to negative control samples, including denatured colZ sample, active colZ showed higher activity (t-test; p < 0.01) (Fig. 3B).
MALDI-TOF MS analysis was used to detect the cleavage products of peptidoglycan incubated with active or denatured colicin Z (Fig. 4). In the MALDI-TOF MS profiles of water-treated PG and PG incubated with denatured purified colicin Z (0.1 mg/ml), no difference was detected during the assessed time-points (i.e., 1 min, 5 min, and 1 hour). In the samples containing PG and the active colicin Z preparation (0.1 mg/ml), a variety of new peaks in the range from 2500 to 14000 m/z was detected following 5 min of incubation.
Discussion
In this work we have identified a novel 26.3 kDa colicin, designated as colicin Z, produced by E. coli strain B1356, with a human origin and active against both EIEC and Shigella strains. Altogether, twenty-five colicin types3,4,18 have been previously characterized and all of them showed a protein domain structure. The only exception was colicin JS, which was found to be considerably smaller than other colicin types with no protein domains identified so far7. The modular structure of colicins appears to allow frequent combinations of the corresponding domains to create new toxic functions in a competitive environment23,24,25. The N-terminal domain of colicin Z showed a low similarity (~40%) to the translocation domain of colicins D and A, and to protein translocase which is in agreement with the localization of translocation domains at the N-termini of most colicin types. Colicin A is Tol-dependent colicin type and colicin D is TonB dependent4 but comparison between translocation domains of colA and colD revealed similar identity (~40%) like comparison of predicted colZ T-domain with colA or colD T-domains. However, the colicin Z protein sequence at the C-terminus shows similarity to colicin JS. Information about colicin JS domain organization is not known but given the fact that the activity spectra of colicins JS and colicin Z were both limited to EIEC and Shigella strains, the C-terminal domain is likely responsible for receptor binding to the CjrC receptor molecule. Following similarity of N-terminal domain of colicin Z to translocation proteins and to translocation domains of colicins A and D, appears unlikely that C-terminal sequence of colicin Z is responsible for the recruitment of the CjrB and ExbBD proteins and for the translocation of colicin Z. The central protein domain of colicin Z shows similarities to enzymes that degrade glycolipids and polypeptides but no similarity to other colicin types suggesting that it is the central part of colicin Z molecule that exerts its (novel) lethal effect. Although not fully experimentally verified, the domain organization of colicin Z appears to be in contrast to previously described colicin types where the central part of the protein is responsible for receptor binding and the C-terminal for the killing activity4. Several S-type pyocin types have their receptor domain at the N-terminus of their molecules26,27 indicating that the positions of individual domains in the antibacterial molecules are not strictly conserved and that colicins could have this unusual molecular organization.
Among the colicin types described to date3,4,18,28, only colicin JS7 and colicin Z selectively kill EIEC and Shigella strains. Enteroinvasive E. coli represent the etiological agents of bacillary dysentery and cause proctocolitis via a nontoxigenic mechanism similar to Shigella strains. In fact, both EIEC and Shigella strains have been shown to be highly related29. The selective activity of colicin Z on EIEC and Shigella strains is a result of the requirement of cjrBC genes (harbored by both EIEC and Shigella strains) for receptor binding and colicin translocation. In addition to the cjrBC genes, colicin Z activity was found to be dependent on ExbB and ExbD. Colicin Z is, similarly as colicin JS, dependent on ExbB. While colicin Z is also dependent on ExbD protein, ΔexbD strains were not previously tested with colicin JS22. CjrB shows similarities to TonB from Gram-negative bacteria and appears to be an EIEC-specific TonB homolog26. CjrC is a homolog of the outer membrane receptors responsible for colicin JS uptake as well as for possible siderophore or heme uptake by Gram-negative bacteria18. ExbB and ExbD are transmembrane proteins of the inner membrane that energize the TonB protein in Gram-negative bacteria30. In known TonB-dependent colicin types (B, Ia, Ib, D, 5, 10, and M), a pentapeptide sequence motif, the TonB-box, was identified near the N-terminus. In colicin Z, similarly to colicin JS7, the TonB box sequence motif was not found and the absence of the TonB box likely results in the tonB-independent translocation of colicin Z and JS mediated by CjrB. Interestingly, while the primary structure of colicin JS and colicin Z are quite different, both molecules are directed against EIEC and Shigella strains suggesting that there is an evolutionary need for the existence of protein molecules that can kill EIEC and Shigella strains. Binding of different colicin types to identical receptor molecules is common and includes BtuB, FepA, Fiu, Cir, and Tsx outer membrane proteins3.
Colicin Z is encoded on a pColZ plasmid that is slightly over 4 kb (4,007 bp). pColZ thus represents the smallest known colicinogenic plasmid; the sizes of previously described colicinogenic plasmids ranged from 5.2 kb to over 75 kb3,4. About 1 kb of pColZ was homologous to plasmid pSF301-1 identified in (S. flexneri) and to plasmid pEC732_5 (E. coli), mainly in regions responsible for plasmid replication, suggesting a common origin of these plasmids. In the remaining part of pColZ, no sequence similarity to previously described plasmids was found. These findings, together with detected differences in the GC content of colicin Z operon and the remaining part of the colicin Z plasmid, suggesting that the pColZ evolved, through DNA recombination from the different sources, relatively recently. No virulence genes were identified on pColZ. Therefore we assume that the main role of this plasmid is colicin Z production.
As revealed through the screening of human commensal and pathogenic as well as veterinary E. coli strains, colicin Z appears to be an extremely rare colicin type among these strains. Previous studies have shown differences in the prevalence of diverse colicin types among the sets of commensal and pathogenic E. coli strains15,16,17,31 with frequencies ranging from 0.1 to 5% for rare colicin types (e.g., colicin N, S4, U, Y, JS) to more than 10% for frequently detected colicin types (e.g., Ia, E1, and M)14,15,16,17,31. The rare occurrence of colicin Z producers appears to be associated with the common susceptibility of EIEC and different Shigella strains to colicin Z. All strains in the set of tested Shigella/EIEC strains (n = 38) isolated between the years 1958–2010 were susceptible to colicin Z. A similar situation was found among strains susceptible to colicin FY, where all tested strains of Yersinia enterocolitica were found susceptible to colicin FY produced by Y. frederiksenii28, likely as a result of the sporadic co-occurrence of both producer and susceptible species32. The extremely rare occurrence of colicin Z producers among tested strains suggests that either colicin Z producers are primarily present in other strains than those tested or it represents sporadic producer strains. In any of these cases, the absence of colicin Z producers may explain the complete susceptibility of the tested EIEC and Shigella strains to colicin Z. In contrast, for several other colicin types, it is estimated that 75% of E. coli strains isolated from different sources are resistant to one or more bacteriocin types and that the resistance to bacteriocins is a successful strategy in antimicrobial competition9,31,33,34.
The colicin Z immunity gene is located downstream from the cza gene with an opposite transcription polarity. Immunity genes with opposite transcription polarity are typical for colicin types acting on the plasma membrane of susceptible bacteria or for colicin M, which inhibits peptidoglycan synthesis4,35. In the killing activity of colicin Z tested with artificial membranes, colicin Z showed almost no pore-forming activity on asolectin membranes. In general, pore-forming colicins are usually very active on asolectin membranes, e.g., colicin A exerts pore-forming activity in the pM concentration range36. Another striking difference was the conductance of individual pores. Colicin A and B are known to form very low-conductance pores of 16 and 21 pS37, respectively, which is still about 6–8 times greater than the conductance of colicin Z pores (2.8 pS). Therefore, our data were inconsistent with the pore-forming activity of colicin Z and the detected pores with low conductance likely reflect some minor contamination of the purified colicin Z preparation.
In the central colicin Z domain, potentially responsible for the lethal effect of colicin Z, a similarity to non-lysosomal glucosylceramidases, metalloproteases, DUF500, and SH3 domain-containing proteins was found. The bacterial Src homology 3 (SH3) domain was reported to bind to the bacterial cell wall38,39,40, and the ‘SH3-like’ domain represents a non-catalytic domain commonly found in bacterial peptidoglycan hydrolases that may interact with carbohydrates and/or poly-proline stretches41. These similarities, together with the transcriptional orientation of the czi gene points to the possibility of colicin Z activity on peptidoglycan. These predictions were further supported by the morphological changes of an indicator bacteria in the transient parts of inhibition zones42, where colicin Z effects resembled the effect of colicin M (data not shown). As shown by peptidoglycan dye-release assays and with MALDI-TOF MS analyses, colicin Z is involved in the degradation of peptidoglycan. Compared to lysozyme (Fig. 3A), the activity of colicin Z was considerably lower and represented only about 15% of lysozyme activity. However, colicins undergo protein unfolding and refolding during receptor binding and translocation4, therefore, soluble colicin Z may have limited activity while lysozyme shows optimum activity in soluble form.
Colicin Z is a novel colicin type that is partially similar to previously described colicin JS, having a narrow inhibitory spectrum and being active only against EIEC and Shigella strains. Colicin Z thus belongs to the group of colicin types (E1, FY, U, Y, and JS) that have been shown to specifically inhibit pathogenic bacteria under in vitro or in vivo conditions22,28,32,43,44,45. At the same time, there appears to be wide susceptibility of EIEC and Shigella strains to colicin Z. These properties of colicin Z suggest a possible future use in therapeutic applications for intestinal shigellosis.
Methods
Bacterial strains
The colicin Z producer strain E. coli B1356 was identified during the screening for bacteriocin production in sets of E. coli (n = 2160) isolated in Brno, Czech Republic13,15,16,17, unpublished results] (Table 1).
The standard colicin indicator strains E. coli K12-Row, C6 (ϕ), 5 K, P400, S40, and Shigella sonnei 17, capable of detecting all known colicin types, were used13,15 in this screening test for bacteriocin producers. In addition, sets of different pathogenic and non-pathogenic strains belonging to different genera (n = 563) were used to identify the inhibitory spectrum of the novel colicin Z (Supplementary Table S1).
The standard bacterial strains were used for cloning, transformation, and protein recombinant expression and purification experiments (Table 1).
A set of knockout strains with gene deletions from the Tol and Ton systems were used25,46,47 [Keio collection, K. Hantke collection] (Table 1).
Prevalence of the colicin Z activity gene (cza) was screened using sets of human and veterinary E. coli (n = 475) (Supplementary Table S2).
Characterization of colicin Z original producer
A total of 20 virulence genes (α-hly, afaI, aer, cnf1, sfa, pap, pCVD432, ial, lt, st, bfpA, eaeA, ipaH, iucC, fimA, pks island, cdt, ehly, stx1, and stx2) and genetic determinants allowing classification into phylogenetic groups (A, B1, B2, and D) were analyzed in E. coli B1356. PCR screening for bacteriocin determinants encoding 24 colicin types (A, B, D, E1-9, Ia, Ib, Js, K, L, M, N, S4, U, Y, FY, and 5/10) and 7 microcin types (mH47, mM, mB17, mC7, mJ25, mL, and mV) was performed. Primer sequences and PCR protocols were previously described15,17,48,49.
Colicin Z activity spectrum
Identification of the colicin Z inhibitory spectrum was performed as described previously13. Briefly, agar plates were inoculated with a stab from a culture of E. coli B1356 and cultivated for 48 hours (37 °C). The bacteria were then killed using chloroform vapors (30 min) and the plates were then overlaid with a thin layer of 0.7%, agar containing 107 cells ml−1 of an indicator strain (overall; n = 563) (Supplementary Table S1) and incubated at 37 °C overnight.
Recombinant DNA methods
For identification of the pColZ plasmid, transposon mutagenesis with a Tn5 transposon (EZ-Tn5™ < KAN-2 > Insertion Kit; Epicentre Biotechnologies, Madison, WI, USA) was used. Briefly, total plasmid DNA from the original producer of colicin Z was isolated using a QIAGEN Plasmid Midi Kit (Qiagen, Germany). This DNA was used in an in vitro transposon insertion reaction and transformed into E. coli DH10B. Plasmid DNA from 24 recombinant colonies (pColZ1-24) was isolated and the DNA in the vicinity of the inserted Tn5 transposon was sequenced (Eurofins Scientific, Brussels, Belgium) with Tn5 transposon sequencing primers (Supplementary Table S3). Next, sequencing primers were designed (Table S3) and plasmid DNA of recombinant strain ColZ1 (which was able to inhibit EIEC O164 indicator strain was used for sequencing of pColZ plasmid).
A non-enzymatic in vivo cloning strategy was used for recombinational cloning to E. cloni® 10 G (Lucigen, Middleton, WI, USA). For in vivo recombination, a digested pBAD/HisB vector (Thermo Fisher Scientific) was prepared and incubated with purified PCR product with 25 nt-long overlaps (Supplementary Table S3) that were complementary to the vector DNA.
Prevalence of the colicin Z activity gene (cza) among E. coli strains of different origins
Overall, 475 various E. coli (Supplementary Table S2) were tested using colony PCR specific for cza gene. The PCR detection protocol was as follows: 94 °C (5 minutes); 94 °C (30 seconds), 60 °C (30 seconds), 72 °C (1 minute), 30 cycles; 72 °C (7 minutes). The cza-F: 5′-ATGAGTGCAAACCCGCATA-3′and cza-R: 5′-TTACTTAGGAAAATCGAAAGTAA-3′ primer pair was used.
Identification of colicin Z receptor
Based on the antimicrobial spectrum of colicin Z which showed similarity to the colicin JS inhibitory spectrum7,22, the role of three genes in the cjr operon (responsible for colJS susceptibility) was analyzed. Combinations of cjrABC genes were cloned into a pBAD/HisB vector (Table 1 and S3) and transformed to E. cloni® 10 G. Clones were verified by sequencing. Next, agar plates were inoculated with a stab of the bacterial culture of E. coli B1356 producer and susceptibility of the different recombinant clones to colZ was tested.
Identification of the colicin Z translocation mechanism
To investigate whether colicin Z is translocated by the Tol or Ton translocation system, different knockout strains were transformed with the recombinant plasmid encoding the colZ receptor - pColZ123 (Table 1). Based on the susceptibility of recombinant clones to colicin Z, the translocation system for colZ was identified.
Colicin Z purification
Recombinant E. coli TOP10F′ strain containing pColZ46 encoding the colicin Z activity gene fused to an N-terminal His tag was constructed and used for purification of the colZ protein. The recombinant strain was cultivated in 20 liters of TY medium (37 °C; 100 rpm) until OD600 reached 0.6, then colicin expression was induced by L-( + )-arabinose (0.2 g/l, Sigma-Aldrich) and cultivated for a further 4 hours (37 °C; 100 rpm). Cells were harvested and frozen at −80 °C. A lysis buffer containing 0.05 M Tris-HCl buffer (pH 7.5), 0.15 M NaCl, 0.001 M EDTA, 0.5% NP40, and one cOmplete™ Protease Inhibitor Cocktail Tablet (Roche, Basel, Switzerland) per 10 ml was added to bacterial pellets and incubated for 30 min on ice. The suspension was homogenized using needle sonication and the cell debris and membranes were removed by ultracentrifugation. His-tagged recombinant colZ was purified using immobilized metal ion affinity chromatography (IMAC) with a Ni Sepharose 6 Fast Flow column (GE Healthcare, Chicago, IL, USA) and eluted using an imidazole gradient (0.01–0.3 M) in 0.05 M Tris-HCl buffer (pH 7.5) containing 0.3 M NaCl. Fractions containing colZ were concentrated and transferred to 50 mM phosphate buffer (pH 7.0) using 3 kDa cut-off membrane ultrafiltration, and the protein concentration was determined using a RC DC Protein Assay (Biorad, Hercules, CA, USA).
The activity of the purified colicin Z protein was tested by spotting 10-fold dilutions on agar plates containing a susceptible E. coli O164. Plates were then incubated at 37 °C overnight and a reciprocal value of the highest dilution of purified colZ causing both clear (complete growth inhibition of the indicator strain) and turbid zones (any detectable growth inhibition of the indicator strain) was used as a description of colicin activity (in arbitrary units, A.U.).
Determination of colicin Z killing mechanism
The pore-forming activity of colicin Z (concentrations up to 340 nM) was tested using conductivity measurements in 1 M KCl, 10 mM HEPES, pH 6 on black lipid membranes composed of DPhPG, E. coli polar lipid extract (Avanti Polar Lipids, Alabaster, AL, USA), or soybean lipids (Asolectin-Type II, Merck KGaA, Darmstadt, Germany). Experiments were performed as described previously50. The effect of colZ on peptidoglycan was tested using the dye release method described in Zhou et al.51. Briefly, RBB3 (Sigma-Aldrich) dyed purified peptidoglycan (50–300 mg/ml in 0.2 M glycine-NaOH, pH 10.0) isolated from EIEC O164 strain were used for measurement of colicin Z activity. Peptidoglycan (PG) isolation from EIEC O164 was performed according to the protocol described by Benešík et al.52. The RBB-released dye was determined spectrophotometrically at 595 nm in three independent measurements (each in two technical replicates). The active colicin Z (0.1 mg/ml) and control reactions were incubated with RBB-PG at 37 °C for 24 h. The controls comprised denatured colicin Z (0.1 mg/ml; heat inactivated for 10 min at 100 °C), distilled water, and lysozyme (0.1 mg/ml) (Sigma-Aldrich). In addition, to assess potential contaminants present in the purified colicin Z, E. coli TOP10F′ containing a control construct represented by an empty pBad/HisB cloning vector was purified in the same way as was the E. coli TOP10F′ colicin Z producer. The resulting control, absent the colZ, was used at the same protein concentration (0.1 mg/ml).
In addition, the detection of peptidoglycan cleavage products was performed using mass spectrometry. Fractions of control commercial PG, isolated from E. coli K12 (InvivoGen, Toulouse, France) (1 mg/ml), and PG incubated (37 °C) with denaturated (0.01 mg/ml) or active colicin Z (0.01 mg/ml) in three different time-points (1 min, 5 min, and 1 hour) were mixed with MALDI matrix (12.5 mg.ml−1 ferulic acid in water:acetonitrile:formic acid mixture, 50:33:17, v/v), applied to a stainless steel sampling target, and analyzed using MALDI-TOF MS using an Ultraflextreme instrument (Bruker Daltonics, Bremen, Germany) operated in the linear positive ion detection mode.
Sequence analysis and construction of phylogenetic trees
The DNASTAR Lasergene package was used for sequence analyses (DNASTAR). The Universal Protein Resource (UniProt) database was used for homology searches of proteins encoded on pColZ (The UniProt Consortium, 2017). ORF finder tool (NCBI) was used for prediction of open reading frames on the plasmid ColZ. Colicin gene or amino acid alignments and phylogenetic trees were computed with Molecular Evolutionary Genetics Analysis (MEGA) version 7.053. DoriC 5.0, a database of oriC regions was used for identification of the pColZ ori site54. The I-TASSER server was used for protein structure prediction and structure-based function annotation55. For prediction of protein subcellular localization, signal peptide sequence identifications, and prediction of transmembrane segments, ExPASy programs (PSORTb, SignalP-5.0, and TMPred) were used56.
Data Availability
All relevant data are within the Manuscript and its Supporting Information files.
References
Majeed, H., Gillor, O., Kerr, B. & Riley, M. A. Competitive interactions in Escherichia coli populations: the role of bacteriocins. ISME J. 5, 71–8 (2011).
Braun, V., Pilsl, H. & Gross, P. Colicins: structures, modes of action, transfer through membranes, and evolution. Arch. Microbiol. 161, 199–206 (1994).
Šmarda, J. & Šmajs, D. Colicins–exocellular lethal proteins of Escherichia coli. Folia Microbiol. (Praha). 43, 563–582 (1998).
Cascales, E. et al. Colicin biology. Microbiol. Mol. Biol. Rev. 71, 158–229 (2007).
Duquesne, S., Destoumieux-Garzón, D., Peduzzi, J. & Rebuffat, S. Microcins, gene-encoded antibacterial peptides from enterobacteria. Nat. Prod. Rep. 24, 708–734 (2007).
Timmis, K. Purification and characterization of colicin D. J. Bacteriol. 109, 12–20 (1972).
Šmajs, D. & Weinstock, G. M. Genetic organization of plasmid ColJs, encoding colicin Js activity, immunity, and release genes. J. Bacteriol. 183, 3949–3957 (2001).
Riley, M. A. & Gordon, D. M. The ecological role of bacteriocins in bacterial competition. Trends Microbiol. 7, 129–133 (1999).
Kerr, B., Riley, M. A., Feldman, M. W. & Bohannan, B. J. Local dispersal promotes biodiversity in a real-life game of rock-paper-scissors. Nature. 418, 171–174 (2002).
Lenski, R. E. & Riley, M. A. Chemical warfare from an ecological perspective. Proc. Natl. Acad. Sci. USA 99, 556–558 (2002).
Wassenaar, T. M. Insights from 100 years of research with probiotic E. coli. Eur. J. Microbiol. Immunol. (Bp). 6, 147–161 (2016).
Azpiroz, M. F., Poey, M. E. & Laviña, M. Microcins and urovirulence in Escherichia coli. Microb. Pathog. 47, 274–280 (2009).
Šmajs, D. et al. Bacteriocin synthesis in uropathogenic and commensal Escherichia coli: colicin E1 is a potential virulence factor. BMC Microbiol. 10, 288 (2010).
Budič, M., Rijavec, M., Petkovšek, Z. & Zgur-Bertok, D. Escherichia coli bacteriocins: antimicrobial efficacy and prevalence among isolates from patients with bacteraemia. PLoS ONE. 6, e28769 (2011).
Micenková, L. et al. Bacteriocin-encoding genes and ExPEC virulence determinants are associated in human fecal Escherichia coli strains. BMC Microbiol. 14, 109 (2014).
Micenková, L., Bosák, J., Vrba, M., Ševčíková, A. & Šmajs, D. Human extraintestinal pathogenic Escherichia coli strains differ in prevalence of virulence factors, phylogroups, and bacteriocin determinants. BMC Microbiol. 16, 218 (2016).
Micenková, L. et al. Human Escherichia coli isolates from hemocultures: Septicemia linked to urogenital tract infections is caused by isolates harboring more virulence genes than bacteraemia linked to other conditions. Int. J. Med. Microbiol. 307, 182–189 (2017).
Rendueles, O., Beloin, C., Latour-Lambert, P. & Ghigo, J. M. A new biofilm-associated colicin with increased efficiency against biofilm bacteria. ISME J. 8, 1275–1288 (2014).
Chan, P. T., Ohmori, H., Tomizawa, J. & Lebowitz, J. Nucleotide sequence and gene organization of ColE1 DNA. J. Biol. Chem. 260, 8925–8935 (1985).
Gillor, O., Vriezen, J. A. & Riley, M. A. The role of SOS boxes in enteric bacteriocin regulation. Microbiology. 154, 1783–92 (2008).
Geli, V., Baty, D., Pattus, F. & Lazdunski, C. Topology and function of the integral membrane protein conferring immunity to colicin A. Mol. Microbiol. 3, 679–87 (1989).
Šmajs, D. & Weinstock, G. M. The iron- and temperature-regulated cjrBC genes of Shigella and enteroinvasive Escherichia coli strains code for colicin Js uptake. J. Bacteriol. 183, 3958–3966 (2001).
Riley, M. A. & Wertz, J. E. Bacteriocins: evolution, ecology, and application. Annu Rev. Microbiol. 56, 117–137 (2002).
Braun, V., Pilsl, H. & Gross, P. Colicins: structures, modes of action, transfer through membranes, and evolution. Arch. Microbiol. 161, 199–206 (1994).
Arnold, T., Zeth, K. & Linke, D. Structure and function of colicin S4, a colicin with a duplicated receptor-binding domain. J. Biol. Chem. 284, 6403–6413 (2009).
Sano, Y., Kobayashi, M. & Kageyama, M. Functional domains of S-type pyocins deduced from chimeric molecules. J. Bacteriol. 175, 6179–6185 (1993).
Michel-Briand, Y. & Baysse, C. The pyocins of Pseudomonas aeruginosa. Biochimie. 84, 499–510 (2002).
Bosák, J. et al. Novel colicin Fy of Yersinia frederiksenii inhibits pathogenic Yersinia strains via YiuR-mediated reception, TonB import, and cell membrane pore formation. J. Bacteriol. 194, 1950–1959 (2012).
Devanga Ragupathi, N. K., Muthuirulandi Sethuvel, D. P., Inbanathan, F. Y. & Veeraraghavan, B. Accurate differentiation of Escherichia coli and Shigella serogroups: challenges and strategies. New Microbes New Infect. 21, 58–62 (2017).
Penfold, C. N., Li, C., Zhang, Y., Vankemmelbeke, M. & James, R. Colicin A binds to a novel binding site of TolA in the Escherichia coli periplasm. Biochem. Soc. Trans. 40, 1469–1474 (2012).
Gordon, D. M. & O´Brien, C. L. Bacteriocin diversity and the frequency of multiple production in Escherichia coli. Microbiology. 152, 3239–3244 (2006).
Bosák, J. et al. Unique activity spectrum of colicin FY: all 110 characterized Yersinia enterocolitica isolates were colicin FY susceptible. PLoS One. 8, e81829 (2013).
Feldgarden, M. & Riley, M. A. High levels of colicin resistance in Escherichia coli. Evolution. 52, 1270–1276 (1998).
Nahum, J. R., Harding, B. N. & Kerr, B. Evolution of restraint in a structured rock–paper–scissors community. Proc. Natl. Acad. Sci. USA 108, 10831–10838 (2001).
Gross, P. & Braun, V. Colicin M is inactivated during import by its immunity protein. Mol. Gen. Genet. 251, 388–396 (1996).
Martinez, M. C., Lazdunski, C. & Pattus, F. Isolation, molecular and functional properties of the C-terminal domain of colicin A. EMBO J. 2, 1501–1507 (1983).
Pressler, U., Braun, V., Wittmann-Liebold, B. & Benz, R. Structural and functional properties of colicin B. J. Biol. Chem. 261, 2654–2659 (1986).
Tettelin, H. et al. Complete genome sequence and comparative genomic analysis of an emerging human pathogen, serotype V Streptococcus agalactiae. Proc. Natl. Acad. Sci. USA 99, 12391–12396 (2002).
Lu, J. Z., Fujiwara, T., Komatsuzawa, H., Sugai, M. & Sakon, J. Cell wall-targeting domain of glycylglycine endopeptidase distinguishes among peptidoglycan cross-bridges. J. Biol. Chem. 281, 549–558 (2006).
Kurushima, J., Hayashi, I., Sugai, M. & Tomita, H. Bacteriocin protein BacL1 of Enterococcus faecalis is a peptidoglycan D-isoglutamyl-L-lysine endopeptidase. J. Biol. Chem. 288, 36915–36925 (2013).
Vollmer, W., Joris, B., Charlier, P. & Foster, S. Bacterial peptidoglycan (murein) hydrolases. FEMS Microbiol. Rev. 32, 259–286 (2008).
Šmajs, D. The morphology of bacterial cells in inhibition zones produced by colicins. Scripta medica (Brno). 5, 171–180 (1995).
Šmajs, D., Pilsl, H., Braun, V. & Colicin, U. a novel colicin produced by Shigella boydii. J. Bacteriol. 179, 4919–4928 (1997).
Patton, B. S., Dickson, J. S., Lonergan, S. M., Cutler, S. A. & Stahl, C. H. Inhibitory activity of colicin E1 against Listeria monocytogenes. J. Food Prot. 70, 1256–1262 (2007).
Bosák, J., Micenková, L., Doležalová, M. & Šmajs, D. Colicins U and Y inhibit growth of Escherichia coli strains via recognition of conserved OmpA extracellular loop 1. Int. J. Med. Microbiol. 306, 486–494 (2016).
Guterman, S. K. & Dann, L. Excretion of enterochelin by exbA and exbB mutants of Escherichia coli. J. Bacteriol. 114, 1225–1230 (1973).
Sun, T. P. & Webster, R. E. Nucleotide sequence of a gene cluster involved in entry of E colicins and single-stranded DNA of infecting filamentous bacteriophages into Escherichia coli. J. Bacteriol. 169, 2667–2674 (1987).
Clermont, O., Bonacorsi, S. & Bingen, E. Rapid and simple determination of the Escherichia coli phylogenetic group. Appl. Environ. Microbiol. 66, 4555–4558 (2000).
Gómez-Moreno, R., Robledo, I. E. & Baerga-Ortiz, A. Direct detection and quantification of bacterial genes associated with inflammation in DNA isolated from stool. Adv. Microbiol. 4, 1065–1075 (2014).
Seydlová, G. et al. Lipophosphonoxins II: Design, Synthesis, and Properties of Novel Broad Spectrum Antibacterial Agents. J. Med. Chem. 60, 6098–6118 (2017).
Zhou, R., Chen, S. & Recsei, P. A dye release assay for determination of lysostaphin activity. Anal. Biochem. 171, 141–144 (1988).
Benešík, M. et al. Role of SH3b binding domain in a natural deletion mutant of Kayvirus endolysin LysF1 with a broad range of lytic activity. Virus Genes. 54, 130–139 (2018).
Kumar, S., Stecher, G. & Tamura, K. MEGA7: Molecular Evolutionary Genetics Analysis Version 7.0 for Bigger Datasets. Mol. Biol. Evol. 33, 1870–1874 (2016).
Gao, F., Luo, H. & Zhang, C. T. DoriC 5.0: an updated database of oriC regions in both bacterial and archaeal genomes. Nucleic Acids Res. 41, D90–93 (2013).
Yang, J. & Zhang, Y. I-TASSER server: new development for protein structure and function predictions. Nucleic Acids. Res. 43, W174–181 (2015).
Artimo, P. et al. ExPASy: SIB bioinformatics resource portal. Nucleic Acids Res. 40, W597–W603 (2012).
Acknowledgements
This work was supported by the Grant Agency of the Czech Republic (16-21649S) and MUNI/A/1087/2018 to DS, and by a project of the Grant Agency of Charles University (390115) to TD. The work was also supported by the European Regional Development Fund-Project “CIISB4HEALTH” (No. CZ.02.1.01/0.0/0.0/16_013/0001776), and by funds from the Faculty of Medicine MU to junior researcher (Juraj Bosák). This study was also partially funded from LM2015051 and CZ.02.1.01/0.0/0.0/16_013/0001761. CIISB research infrastructure project LM2015043 funded by MEYS CR is gratefully acknowledged for the financial support of the MALDI-MS measurements at the Proteomics Core Facility. We would like to thank Thomas Secrest (Secrest Editing, Ltd.) for the English editing of the manuscript.
Author information
Authors and Affiliations
Contributions
L.M. and D.Š. conceived and designed the study. L.M. performed the experiments together with J.B., J.K., M.H., T.D., O.Š. and R.F. and L.M. wrote the first draft of the manuscript; J.B., D.L. and D.Š. contributed to the writing of the manuscript. All authors reviewed and approved of the final manuscript.
Corresponding author
Ethics declarations
Competing Interests
The authors declare no competing interests.
Additional information
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Micenková, L., Bosák, J., Kucera, J. et al. Colicin Z, a structurally and functionally novel colicin type that selectively kills enteroinvasive Escherichia coli and Shigella strains. Sci Rep 9, 11127 (2019). https://doi.org/10.1038/s41598-019-47488-8
Received:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41598-019-47488-8
This article is cited by
-
Escherichia coli has an undiscovered ability to inhibit the growth of both Gram-negative and Gram-positive bacteria
Scientific Reports (2024)
-
Revisiting the Multifaceted Roles of Bacteriocins
Microbial Ecology (2024)
-
Dynamics of ColicinE2 production and release determine the competitive success of a toxin-producing bacterial population
Scientific Reports (2020)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.